Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCD-Omegatex in Sickle Cell Disease
NCT02947100Phase 2Terminated
- Sponsor
- Robin E. Miller
- Start
- Jan 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SCD-Omegatex in sickle cell disease (SCD), sponsored by Robin E. Miller. Primary endpoints: Clinical Safety as Evidenced by an Absence of Adverse Events at 6 months and Reduction in Thermal Sensitivity by Quantitative Sensory Testing at 6 months. Started Jan 2018; status: terminated.
02
Drugs
SCD-Omegatex
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02947100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947100.